Trethera Announces Prostate Cancer Poster Presentation At The American Association For Cancer Research Annual Meeting
Safety Review Committee Advances Trethera Phase 1 Solid Tumors Trial to Next Dose After First Patient Cohort Achieves Primary Endpoint
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis
Trethera Doses First Patient in Landmark Clinical Trial for the Treatment of Solid Tumors With First-In-Class Drug TRE-515
Globally Recognized Multiple Sclerosis Expert, Dr. Lawrence “Larry” Steinman, Joins Trethera Scientific Advisory Board
Trethera Receives FDA Approval To Initiate TRE-515 Phase 1 Clinical Trial in Solid Tumors Monotherapy
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis
